Scarica l'app Stockscreener
1.60
0.00%
0.00
Dopo l'orario di chiusura:
1.60
Precedente Chiudi:
$1.60
Aprire:
$1.61
Volume 24 ore:
239.71K
Relative Volume:
0.48
Capitalizzazione di mercato:
$31.18M
Reddito:
-
Utile/perdita netta:
$-40.94M
Rapporto P/E:
-0.4167
EPS:
-3.84
Flusso di cassa netto:
$-22.97M
1 W Prestazione:
-3.61%
1M Prestazione:
-36.51%
6M Prestazione:
-81.35%
1 anno Prestazione:
-82.24%
Intervallo 1D:
$1.525
$1.68
Intervallo di 1 settimana:
$1.525
$1.7727
Portata 52W:
$1.525
$20.00
Annovis Bio Inc Stock (ANVS) Company Profile
Nome
Annovis Bio Inc
Settore
Industria
Telefono
484-875-3192
Indirizzo
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Confronta ANVS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
1.60 | 31.18M | 0 | -40.94M | -22.97M | -3.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-10 | Downgrade | D. Boral Capital | Buy → Hold |
| 2024-10-25 | Aggiornamento | Maxim Group | Hold → Buy |
| 2023-12-29 | Iniziato | Canaccord Genuity | Buy |
| 2021-07-07 | Reiterato | Maxim Group | Buy |
Annovis Bio Inc Borsa (ANVS) Ultime notizie
Annovis Bio stock hits 52-week low at $1.55 amid sharp decline - Investing.com India
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment - GlobeNewswire
Revolutionary Parkinson's Treatment: Annovis Unveils Phase III Data for Multi-Target Drug - StockTitan
LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight - GlobeNewswire Inc.
Atria Wealth Solutions Inc. Purchases Shares of 13,002 Annovis Bio, Inc. (NYSE:ANVS) - Defense World
Annovis Bio stock hits 52-week low at $1.72 amid market challenges - Investing.com Australia
ANVS ALERTLabaton Sucharow Announces the Filing of a Securities Class Action Against Annovis Bio, Inc.; Investors Encouraged to Contact the Firm Before October 18 - ACCESS Newswire
Annovis Bio stock hits 52-week low at $1.72 amid market challenges By Investing.com - Investing.com South Africa
Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments - MSN
Annovis Bio stock hits 52-week low at $2.42 amid market challenges By Investing.com - Investing.com South Africa
Annovis Bio stock hits 52-week low at $2.42 amid market challenges - Investing.com Australia
Annovis to Host Patients’ Live Forum on February 27, 2025 - GlobeNewswire
Annovis to Host Patients' Live Forum on February 27, 2025 - Quantisnow
Inside Annovis's Groundbreaking Alzheimer's Trial: CEO Opens Direct Dialogue With Patients - StockTitan
Annovis Bio stock hits 52-week low at $2.59 amid sharp decline - MSN
Annovis Bio stock rating cut to hold at D. Boral Capital - MSN
Annovis Bio stock hits 52-week low at $2.59 amid sharp decline By Investing.com - Investing.com South Africa
Annovis Bio CEO to Present at Oppenheimer Healthcare Life Sciences Conference - MSN
Annovis Bio Launches Phase 3 Trial for Alzheimer’s Drug Buntanetap - MSN
Annovis Bio begins pivotal phase 3 Alzheimer's drug trial - MSN
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Annovis Bio Raises $21 Million in Public Offering to Advance Alzheimer’s Research - MSN
Annovis Bio Inc. CEO to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference on Pivotal Phase 3 Trial Progress - Nasdaq
Annovis to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference - Hamilton Spectator
Annovis Bio (NYSE: ANVS) CEO To Present At Oppenheimer Healthcare Conference - Barchart
Annovis begins treatment of subjects in Alzheimer’s trial - Yahoo Finance
Annovis Bio begins pivotal phase 3 Alzheimer's drug trial By Investing.com - Investing.com Australia
Annovis Bio announces first patients entered Phase 3 study of buntanetap - Yahoo Finance
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease - GlobeNewswire
Annovis Bio stock hits 52-week low at $4.05 amid market challenges - MSN
Annovis Bio sets terms for $21 million public offering - MSN
Annovis Bio completes $21 million stock and warrant offering - MSN
Annovis Bio Enrolls First Patients in Phase 3 Trial of Buntanetap for Early Alzheimer's Disease - Marketscreener.com
Annovis Bio Launches Phase 3 Alzheimer’s Study - TipRanks
Annovis Bio Inc Azioni (ANVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.14%
2.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):